All In Biotech

NDA 021301 · King Pharms

Levoxyl

Levothyroxine Sodium · Oral

Last checked: Nov 20, 2026Latest source record: Dec 20, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

May 25, 2001

Approved uses

1

Original approval plus efficacy supplements

Registered trials

216

36 Phase 3, 17 recruiting

FAERS reports

117,966

78,189 serious, 9,123 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS • Thyroid hormones, including LEVOXYL, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. • In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , Overdosage (10) ] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. • Thyroid hormones, including LEVOXYL, should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily hormonal requirements may produce...

What it is approved for

From the label in effect Nov 6, 2026.

LEVOXYL is L-thyroxine (T4) indicated in pediatric and adult patients for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer. ( 1 ) Limitations of Use : ‐ Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. ( 1 ) ‐ Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. ( 1 ) Hypothyroidism LEVOXYL is indicated in pediatric and adult patients as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression LEVOXYL is indicated in pediatric and adult patients as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer . Limitations of Use : • LEVOXYL is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with LEVOXYL may induce hyperthyroidism [see Warnings and Precautions (5.4) ] . • LEVOXYL is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

Mechanism: Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 25, 2001 Original approval · Type 5 - New Formulation or New Manufacturer LetterReviewLabel
12 products under this application
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3
  • LEVOXYL · LEVOTHYROXINE SODIUM 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET, ORAL · Prescription · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Levothyroxine" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue9,546
  • nausea8,421
  • diarrhoea7,430
  • headache7,381
  • dyspnoea7,101
  • drug ineffective6,732
  • pain6,113
  • dizziness6,004
  • asthenia5,071
  • vomiting5,065
  • malaise4,758
  • fall4,636

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,816
20052,856
20062,997
20073,561
20084,841
20094,584
20105,683
20117,244
20128,049
20132,724
20142,580
20153,359
20163,998
20174,313
20184,690
20194,493
20205,872
20216,102
20227,752
20237,252
20247,625
20258,520
20266,054

Recalls

28 FDA enforcement reports for this application.

  • Sep 29, 2026 · Class II · Ongoing

    Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

  • Sep 29, 2026 · Class II · Ongoing

    Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

  • Jul 29, 2025 · Class II · Ongoing

    Subpotent drug

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Dec 6, 2018 · Class II · Terminated

    Superpotent Drug.

  • Nov 7, 2016 · Class II · Terminated

    Superpotent

  • Apr 30, 2013 · Class II · Terminated

    Subpotent Drug: The products were below specification for potency at the expiry stability point.

  • Apr 30, 2013 · Class II · Terminated

    Subpotent Drug: The products were below specification for potency at the expiry stability point.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Levoxyl (Levothyroxine Sodium)

2024 spending

$6.1M

Beneficiaries

39,693

157,517 claims

Per beneficiary

$154

$0.52 per unit

View as table
YearSpending
2020$6,225,783
2021$6,269,942
2022$5,405,524
2023$4,773,667
2024$6,102,490

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 611 on PubMed

Sponsor: King Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.